Preview

Российский кардиологический журнал

Расширенный поиск

СОВЕТ ЭКСПЕРТОВ. ТЕКУЩАЯ ПОЗИЦИЯ ПО БИВАЛИРУДИНУ

Полный текст:

Об авторе

статья Редакционная

Россия


Список литературы

1. Stone GW, et al. Reduction in Cardiac Mortality With Bivalirudinin Patients With and Without Major Bleeding. J Am Coll Cardiol 2014; 63:15-20.

2. Coons JC, et al. Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations. Pharmacotherapy 2014; doi: 10.1002/phar.1447).

3. 2014 ESC/EACTS Guidelines on myocardial revascularization. S. Windecker, et al. European Heart Journal Advance Access published August 29, 2014.

4. Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization. REPLACE-2 Randomized Trial. A. M. Lincoff, et al. JAMA. 2004; 292: 696-703.

5. Kastrati A, et al. Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. N Engl J Med 2008; 359: 688-96.

6. Stone GW, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369: 907-19.

7. Kastrati A, et al. Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction. N Engl J Med 2011.10.1056/NEJMoa1109596) November 13, 2011. NEJM.org.

8. Stone GW, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2009; 374: 1149-59.

9. Steg PG, et al. Bivalirudin Started during Emergency Transport for Primary PCI. DOI: 10.1056/ NEJMoa1311096. October 30, 2013, at NEJM.org.

10. Clemmensen P . Predictors associated with acute stent thrombosis after primary PCI: Insights from the Euromax trial. Presented at the American College of Cardiology (ACC) i2 annual scientific Session; March 29, 2014; Washington, DC.

11. Dangas GD, et al. Predictors of Stent Thrombosis After Primary PCI and Risk for 30-Day Mortality: Analysis from the pooled patient-level data from the HORIZONS-AMI and EUROMAX trials. TCT 2014. Featured Clinical Research; JACC 2014.

12. S hahzad A, et al.Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014 Nov 22; 384(9957): 1849-58.

13. Parodi G, et al. Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2015; 8:e001593. DOI: 10.1161/CIRCINTERVENTIONS.

14. Hobl EL, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014 Feb 25; 63(7): 630-5.


Для цитирования:


СОВЕТ ЭКСПЕРТОВ. ТЕКУЩАЯ ПОЗИЦИЯ ПО БИВАЛИРУДИНУ. Российский кардиологический журнал. 2015;(2):100-103.

For citation:


Редакционная с. EXPERT CONSENSUS. THE CURRENT POSITION ON BIVALIRUDIN. Russian Journal of Cardiology. 2015;(2):100-103. (In Russ.)

Просмотров: 105


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)